| |
 |
This is the category page. Below are all of the research programs that are associated with it
- ISOLATED LIMB INFUSION REGISTRY PROTOCOL
(2_20080910_118)
This study is to open a database for any patient who has or will have Isolated Limb Infusions of a leg or arm. This study is for participants with melanoma and/or sarcoma. The registry will have no end date, it will be ongoing.
- ISOLATED LIMB INFUSION REGISTRY PROTOCOL (Version 1.0 dated 7/24/2008, consent version dated 7/24/2008)
(2_20080910_118)
This study is to open a data base for any patient who has or will have Isolated Limb Infusions of a leg or arm. This study is for participants with melanoma and/or sarcoma. This registry study will have no end date, it will be ongoing.
- Melanoma Patients and Healthy volunteers:
DEVELOPMENT OF TARGETED TUMOR-BINDING IMMUNOTHERAPEUTICS (Investigator Initiated Protocol)
(2_20090505_118)
Participants will have a blood sample taken from healthy adult donors, and from patients diagnosed with melanoma. These samples will be used by scientist for use in identifying small molecules. There will be no actual treatments.
- Melanoma, Metastatic -
NCCTG #N0675: A PHASE II STUDY OF TEMOZOLOMIDE AND EVEROLIMUS (RAD-001) THERAPY FOR METASTATIC MELANOMA)
(1_20080409_118)
This study will use a non-FDA approved drug, everolimus, along with a FDA approved drug, temozolomide. This is a Phase II, single arm study, giving participants standard oral chemotherapy, temozolomide along with the experimental oral drug, everolimus. Starting with day one, everolimus is given for five days on, two days off, continuing for 5 weeks. The first cycle will consist of 35 days and all subsequent cycles will consist of 28 days. During the first course of treatment, temozolomide will be given for 5 days, starting on day 8 through 12, only. During all subsequent cycles, temozolomide will be give day 1-5 with everolimus. Participants will be monitored for adverse events closely.
- Melanoma:
ECOG-E2607: A PHASE II TRIAL OF DASATINIB IN PATIENTS WITH UNRESECTABLE LOCALLY ADVNACED OR STAGE IV MUCOSAL, ACRAL AND SOLAR MELANOMAS
(1_20090709_118)
This study is for patients with unresectable melanoma or stage IV of the skin, including soles of feet, palms of hands and mucosal sites such as mouth, eyes, etc. One cycle runs for 21 days. Participants will take the dasatinib, an FDA approved drug, twice a day for 21 day cycles. Participants may continue until disease progression or unacceptable side effects. Before starting the first cycle participants will need to undergo a brain MRI, CT or MRI of chest, abdomen & pelvis, EKG, Bone Scan and required blood work. While on study, your doctor may require additional testing as he feels is indicated. Follow-up for five years after stopping treatment.
- Study Closed to Accrual -
Melanoma -
NCCTG #N0775: A RANDOMIZED PHASE II TRIAL OF TEMOZOLOMIDE (TMZ) AND AVASTIN OR ABI-007/CARBOPLATIN (CBDCA) AND AVASTIN IN PATIENTS WITH UNRESECTABLE STAGE IV MALIGNANT MELANOMA
(2_20081111_118)
A Randomized Phase II Trial studying the side effects of multiple drugs in patients with Stage IV Malignant Melanoma that is unresectable. Participants will be assigned to one of two experimental arms. Patients will be assigned to the specific arm according to ECOG performance status and location of disease. Treatment will repeat every 28 days until disease progression or unacceptable side effects. Patients will be followed periodically with blood samples.
- Study Closed to Accrual:
Melanoma, Stage III or IV -
OPEN LABEL, SINGLE ARM, PHASE I/II STUDY OF CADI-05 IN PATIENTS WITH ADVANCED STAGE III OR STAGE IV MELANOMA (Investigator Initiated Protocol)
(1_20061206_118)
All participants will have blood work drawn as a baseline which will be used to monitoring the response to therapy. Some participants may be required to have a pre-treatment biopsy. Participants whose tumor is not easily accessible, will undergo one intradermal injection of CADI-05 twice per week for four weeks and then one per week for four weeks. Participants who have accessible tumors that can be safely accessed for injection, half of the dose will be administered directly into the tumor and half of the dose will be administered via standard intradermal fashion. If treatment is tolerated well and there is no disease progression, participants may continue for three additional cycles.
|
|
